Testosterone ester
Testosterone Phenylpropionate
Testosterone Phenylpropionate after one dose: 50% at ~1.5 days, 25% at 3 days, 12.5% at 4.5 days.
Drawn from the half-life in the app's model, ~1.5 days. The model's figures
- Compound
- Testosterone Phenylpropionate
- Symbol
- TPP
- Family
- Testosterone esters
- Parts
- 14
- References
- 14
- Checked
- Last reviewed . Sources are listed below.
Overview
Testosterone phenylpropionate is the 3-phenylpropanoate ester of testosterone, with the molecular formula C28H36O3 and a molecular weight of 420.6.3
On the UK label of Sustanon 250 (Aspen), each 1 ml ampoule holds 30 mg testosterone propionate, 60 mg testosterone phenylpropionate, 60 mg testosterone isocaproate and 100 mg testosterone decanoate in refined arachis oil, and the label gives the total amount of testosterone as 176 mg per ml.1 The New Zealand data sheet lists the same four esters at the same amounts and the same 176 mg of testosterone per 1 mL.4
The UK label gives the indication as "Testosterone replacement therapy for male hypogonadism, when testosterone deficiency has been confirmed by clinical features and biochemical tests", and adds that "Testosterone administration may also be used as supportive therapy for female-to-male transsexuals." Every label statement here concerns that four-ester product, not the phenylpropionate ester alone.1
A search of PubMed on 16 November 2026 for "testosterone phenylpropionate" in the title or summary text returned 22 records; 7 of them carry the MeSH term Humans and 2 carry a clinical trial or randomized controlled trial publication type. In the human records whose summaries describe a product given to people, the ester was part of a mixture of testosterone esters: the four-ester Sustanon formulation or a three-ester combination.5,6,7 A search of ClinicalTrials.gov for the phrase as an intervention returned 1 study, a trial of the four-ester injection.8 Of the 22 records, 20 summaries were read; of the studies cited here, only Turza and colleagues (2022) and Gharahdaghi and colleagues (2019) were read in full.
How it works
The UK label states that "The esters are hydrolysed into the natural hormone testosterone as soon as they enter the general circulation."1 Solheim and colleagues (Drug Testing and Analysis, 2022) describe direct detection of intact testosterone esters in doping control samples as "hampered by the rapid hydrolysis by esterases present in the blood"; with dried blood spots, they write, "continued degradation of the esters is avoided due to inactivation of the hydrolase enzymes in dried blood".9 Intact esters were nonetheless measured in blood after injection (Forsdahl and colleagues, 2015) and in dried blood spots (Solheim and colleagues, detection window up to 14 days for three of the esters); the sources do not reconcile this with the label's wording.5,9
The label adds that testosterone shows over 97% non-specific binding to plasma proteins and sex hormone binding globulin in in vitro tests and is metabolised to dihydrotestosterone and estradiol.1
For the four-ester product in hypogonadal men, the label states that treatment "results in a clinically significant rise of plasma concentrations of testosterone, dihydrotestosterone, estradiol and androstenedione, as well as decrease of SHBG".1 That statement describes the blend as a whole.
Deeper analysis: crystal structure and oil solubility (Turza and colleagues, 2022)
Turza and colleagues (Materials, 2022; National Institute for R&D of Isotopic and Molecular Technologies and Technical University of Cluj-Napoca, Romania) determined crystal structures of testosterone propionate, phenylpropionate and isocaproate by single-crystal X-ray diffraction, and compared them with testosterone base and the acetate ester.2
They measured the solubility of the four esters (acetate, propionate, isocaproate, phenylpropionate) at room temperature (25 °C) in six oil mixtures, each made of 78% oil, 20% benzyl benzoate and 2% benzyl alcohol by volume.2 The authors report that "Propionate and phenylpropionate esters have similar and slightly higher values than acetate" and that the isocaproate has "a roughly four-fold greater solubility" than the acetate; the mg per mL values themselves sit in a supplementary table.2
The authors also write that "solubility correlates with the half-life of the prodrug", but in the same passage they note that although phenylpropionate has six more carbon atoms than propionate, "the solubilities are similar" and "the phenyl ring does not lead to an increase in solubility"; their introduction gives 1 day for propionate and 2.5 days for phenylpropionate.2 The work is laboratory chemistry on the powders; it measured no half-life and reports no blood levels in people or animals. It was funded by the Romanian Ministry of Research and Innovation (grant number 19 35 02 02), and the authors declare no conflict of interest.2
Pharmacokinetics
The figures at the top of the page are the app's: a half-life of 36 hours (about 1.5 days), a bioavailability of 95%, a typical dose of 50-100 mg, a time to peak of 36 hours and an intramuscular route. The app also lists a duration of about 72 hours.
Beside the app's half-life, Turza and colleagues (2022) write in their introduction: "The esterified forms of testosterone possess a half-life ranging from around less than 1 day for testosterone acetate, 1 day for propionate, 2.5 days for phenylpropionate, and up to 3.1 days for testosterone isocaproate", and cite a 2015 paper on detecting testosterone esters in blood for that statement.2 The PubMed summary of that 2015 paper by Forsdahl and colleagues gives no half-life figure; it states that "The detection time depended on the type of ester administered."5
| Source | Measure | Product and dose | Value |
|---|---|---|---|
| The app | Half-life, time to peak, bioavailability, duration | Testosterone phenylpropionate, IM | 36 h, 36 h, 95%, 72 h |
| Turza and colleagues, 20222 | Half-life, stated in the introduction | Phenylpropionate ester; no dose; the statement cites a 2015 paper | 2.5 days (1 day for propionate; up to 3.1 days for isocaproate) |
| UK label, Sustanon 2501 | Total plasma testosterone after one dose | Four-ester blend, single dose; dose, population and number of people not stated in the label | Cmax approximately 70 nmol/l; tmax approximately 24-48 h; back to the lower limit of the normal range in males in approximately 21 days |
| Katz and colleagues, 199310 | Testosterone concentrations after intramuscular injection | Mix of propionate 15 mg, phenylpropionate 30 mg, isocaproate 30 mg and decanoate 50 mg; patients with beta thalassaemia major and hypogonadism; sampling times not stated in the summary | Peak values seven days after injection |
Values from the Milligram app's model.
- Half-life
- ~1.5 days
- Bioavailability
- 95%
- Typical dose
- 50–100 mg
- Route
- IM
- Time to peak
- ~36 h
The New Zealand data sheet for the same product gives the same peak level of approximately 70 nmol/l and the same return to the lower limit of the normal range in approximately 21 days.4 Both are for total plasma testosterone after the blend, not the ester by itself.
The labels, the registry entry and the papers or summaries cited here report no bioavailability figure, no typical dose, no duration of action and no time to peak for the phenylpropionate ester given alone, so the app's 95%, 50-100 mg, 72 hours and 36 hours have no figure from these sources beside them.
Human studies
Where the studies below describe the ester, it was given inside a mixture of testosterone esters, so no result belongs to phenylpropionate alone; in the Forsdahl studies some participants instead received 1000 mg testosterone undecanoate, a single-substance preparation.5,6
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Katz and colleagues, 199310 | Pharmacokinetic evaluation of oral, intramuscular and transdermal replacement | 21 male (16-29 years) and 11 female (19-26 years) patients with beta thalassaemia major and various forms of hypogonadism; the number given the intramuscular mix is not stated | Intramuscular mix: propionate 15 mg, phenylpropionate 30 mg, isocaproate 30 mg, decanoate 50 mg | Intramuscular testosterone produced peak values seven days after injection; sampling times not stated in the summary |
| Büyükgebiz, 19957 | Treatment series, followed 2 years; no comparison group described | 13 boys with constitutional delayed puberty, mean age 14.9 +/- 0.6 years | 200 mg testosterone intramuscular 4 times at 3-week intervals (propionate, phenylpropionate, isocaproate) | All 13 entered puberty after the last dose; growth rate 4.5 +/- 0.5 to 8.4 +/- 1.6 cm/year; height for bone age SD score -1.1 to -1.3, not significant |
| Gharahdaghi and colleagues, 201911 | Randomized, double-blind, placebo-controlled, with resistance training | 18 healthy non-hypogonadal men aged 65 to 75 years (9 per group) | Sustanon 250 mg or saline placebo every two weeks over 6 weeks | Total fat-free mass gain larger with testosterone (P=0.007); estimated absolute muscle protein breakdown also higher (P=0.02); no adverse events reported |
| Solheim and colleagues, 20229 | Dried blood spot detection study, placebo-controlled | Men receiving Sustanon 250 (n = 9) or placebo (n = 10) | Two intramuscular injections of Sustanon 250 | Sustanon detected in all subjects for at least 5 days; window up to 14 days for three of the esters, not named in the summary |
| Forsdahl and colleagues, 20155 | Clinical study of detection windows in serum and plasma | Six participants in total, receiving either product | Single intramuscular injection of 1000 mg testosterone undecanoate or of the four-ester mixture (60 mg phenylpropionate); blood collected over 60 days | All esters detected; detection time depended on the ester; short-chained ester concentrations depended on the collection device, detection window comparable |
| ClinicalTrials.gov NCT01454011, record of 20118 | Phase 4, non-randomized, parallel, open label | 140 enrolled (actual); congenital hypogonadotrophic hypogonadism patients and healthy controls | Four-ester injection (Sustanon 250 mg ampule) at 3-week intervals against testosterone gel 50 mg | No results posted on the record |
Deeper analysis: Büyükgebiz (Hormone Research, 1995)
Büyükgebiz (Department of Pediatric Endocrinology, Dokuz Eylül Medical Faculty, Izmir, Turkey) treated 13 boys with constitutional delayed puberty with a combination of testosterone propionate, phenylpropionate and isocaproate and followed them for 2 years; predicted height was 173.5 +/- 6.6 cm before and 173.3 +/- 4.9 cm after, with no significant change in height for bone age SD score, and the author concludes that the combination "in a given dose and schedule is a safe and effective treatment for prepubertal boys with CDP".7 The PubMed record describes no comparison group or blinding, gives no adverse-event figures, and states neither a funder nor the amount of each ester. The UK label states for the four-ester product that "Safety and efficacy have not been adequately determined in children and adolescents."1 A second PubMed record by the same author (Turkish Journal of Pediatrics, 1993) gives the same 13 boys, dose, follow-up and results, so the two appear to be one series.14
Deeper analysis: Gharahdaghi and colleagues (Journal of Cachexia, Sarcopenia and Muscle, 2019)
Gharahdaghi and colleagues (Universities of Nottingham and Birmingham, United Kingdom) randomized 18 healthy, non-hypogonadal men aged 65 to 75 years to biweekly injections of saline placebo (n = 9) or "Sustanon 250 mg" (n = 9) over 6 weeks of resistance training.11 Testosterone was associated with greater gains in total fat-free mass (P=0.007) and appendicular fat-free mass (P=0.001), a decrease in total fat mass (P=0.02) and larger gains in sum strength (P=0.0009). Estimated absolute muscle protein breakdown was also higher with testosterone (140.2 versus 90.2 g/day, P=0.02), while a 3-methylhistidine measure showed no significant difference in breakdown (P=0.5).11 The authors state that "No adverse events were reported during or after completion of the study." The methods describe only that participants "were monitored throughout the study for any negative side effects of T injections"; the groups were 9 men each over about 6 weeks, and the paper reports no haematocrit or PSA results.11 Discussing testosterone trials in general, not this study, the authors write that randomized controlled trials "have been insufficiently powered to detect differences in the rates of adverse events", that "some have reported an increased risk of stroke and/or myocardial infarction", and that therapy has been associated with non-significant increases in cardiovascular risk and prostate hypertrophy.11 The Medical Research Council and the National Institute for Health Research funded the work and the authors declare no conflict of interest. The result belongs to the blend, in men who were not hypogonadal, unlike the population in the UK label indication.11,1
Deeper analysis: detection studies in doping control (Forsdahl, Solheim and colleagues)
Forsdahl and colleagues (Seibersdorf doping control laboratory, Austria, and the University of Tromsø; Drug Testing and Analysis, 2015) gave six participants one injection of 1000 mg testosterone undecanoate or of the four-ester mixture and sampled blood for 60 days. They report that "All investigated testosterone esters could be detected in post-administration blood samples" and that "The detection time depended on the type of ester administered."5 The PubMed record does not state the split of the six participants between products or a funder.5
Solheim and colleagues (University of Copenhagen, Anti-Doping Denmark and Oslo University Hospital; Drug Testing and Analysis, 2022) report a method suitable for direct detection of four esters, among them phenylpropionate, in dried blood spots from men given two injections of Sustanon 250 (n = 9) or placebo (n = 10); "Sustanon® was detected in all subjects for at least 5 days, with detection window up to 14 days for three of the esters." The summary does not say which three, or whether phenylpropionate was among them. The PubMed record lists Anti Doping Denmark, the Innovation Fund and the Partnership for Clean Competition as funders.9
Doses reported in studies and on labels
The labels and study summaries below give amounts for the four-ester or three-ester products; none states a dose of testosterone phenylpropionate given alone.
| Source | Product | Phenylpropionate stated | Schedule reported |
|---|---|---|---|
| The app | Testosterone phenylpropionate, IM | 50-100 mg | No schedule in the app's figure |
| UK label1 | Sustanon 250, 1 ml ampoule | 60 mg per ampoule | Adults (including elderly): "Usually, one injection of 1ml per 3 weeks is adequate", with the dose adjusted to the response of the individual patient in general; female-to-male transsexuals: one injection of 1 ml every two weeks to every four weeks, as used by different specialist centres1 |
| Katz and colleagues, 199310 | Four-ester mix, intramuscular | 30 mg | Not stated in the PubMed summary; its conclusions mention smaller intramuscular doses of 10-25 mg every one to two weeks in these patients |
| Büyükgebiz, 19957 | Three-ester combination, intramuscular | Not stated; 200 mg testosterone in total | Four doses at 3-week intervals; 2 years of follow-up |
| Gharahdaghi and colleagues, 201911 | Sustanon 250 | Not stated | Every two weeks over 6 weeks |
Side effects reported
Sources in this part
No study summary or paper cited here reports side effects of testosterone phenylpropionate given alone. For the four-ester product, the UK label states that "The following adverse reactions have been associated with androgen therapy in general" and that "Injectables in general, may cause a local reaction at the injection site."1
The label's table of reactions associated with androgen therapy in general lists, with the frequency "Not known": prostatic cancer (progression of a sub-clinical prostatic cancer), polycythaemia, fluid retention, depression, nervousness, mood altered, libido increased and decreased, hypertension, nausea, hepatic function abnormal, pruritus, acne, myalgia, ejaculation disorder, gynaecomastia, oligospermia, priapism, benign prostatic hyperplasia and, under Investigations, abnormal lipids and increased PSA, haematocrit, red blood cell count and haemoglobin.1 Weight increased is listed as common and pulmonary oil microembolism as rare; the Investigations row ends "Not known Common", so the table does not make clear which of its terms is common.1 It also states that "In men treatment with androgens can lead to fertility disorders by repressing sperm-formation."1
On abuse, the label states: "Abuse of testosterone and other anabolic androgenic steroids can lead to serious adverse reactions including: cardiovascular (with fatal outcomes in some cases), hepatic and/or psychiatric events."1 The label's contraindications are pregnancy, breast-feeding, known or suspected carcinoma of the prostate or breast, and hypersensitivity to the active substance or an excipient including arachis oil (refined), so the product is contraindicated in patients allergic to peanuts or soya.1
The label states that the product contains 100 mg benzyl alcohol per ml solution and "must not be given to premature babies or neonates", and that benzyl alcohol "may cause toxic reactions and anaphylactoid reactions in infants and children up to 3 years old".1 Its special warnings also name reports of thrombotic events (deep-vein thrombosis, pulmonary embolism, ocular thrombosis) in patients with thrombophilia or risk factors for venous thromboembolism, sleep apnoea, and, in patients with severe cardiac, hepatic or renal insufficiency or ischaemic heart disease, "severe complications characterised by oedema with or without congestive cardiac failure".1
Of the human studies above, only the 2019 randomized trial gives an adverse-event statement ("No adverse events were reported during or after completion of the study", 9 men on Sustanon 250 for 6 weeks); the PubMed summaries of the other studies report no adverse-event counts.11
Bloodwork and markers
Sources in this part
The app lists total testosterone, free testosterone, estradiol, hematocrit, lipids and PSA as the markers it tracks for this ester.
The UK label for the four-ester product lists monitoring of testosterone level at baseline and at regular intervals, and names digital rectal examination of the prostate with PSA, haematocrit and haemoglobin, and, in long-term androgen therapy, liver function tests and lipid profile.1 The app's list and the label's list overlap on testosterone level, haematocrit, lipids and PSA; the app also lists free testosterone and estradiol, and the label also names haemoglobin, liver function tests and digital rectal examination.1
Separately, in a doping-control study of urinary steroid conjugates, Forsdahl and colleagues (Steroids, 2020) gave six healthy volunteers one injection of 1000 mg testosterone undecanoate or of the four-ester mixture, collected urine for 60 days and report that "urinary changes in both sulfo - and glucuro conjugated steroid levels are prominent after the injection of testosterone esters".6
Regulatory and anti-doping status
Testosterone is named in section S1.1 (anabolic androgenic steroids) of the World Anti-Doping Agency 2026 Prohibited List, in the class S1 anabolic agents, which is prohibited at all times, in and out of competition.12 The section applies "When administered exogenously", and the closing words of S1.1 add "and other substances with a similar chemical structure or similar biological effect(s) including their esters".12 The text of the list does not print the word phenylpropionate.12
The UK label states that Sustanon 250 "can interfere with anti-doping testing" and refers patients in competitions governed by the World Anti-Doping Agency to the WADA code.1
Detection of the intact ester is a published doping-control approach. Forsdahl and colleagues (2015) write that "the detection of an intact ester of testosterone in blood gives unequivocal proof of the administration of exogenous testosterone".5 Tretzel and colleagues (Journal of Pharmaceutical and Biomedical Analysis, 2014) built a dried blood spot screening assay that includes testosterone phenylpropionate among eight anabolic steroid esters.13 Solheim and colleagues (2022) describe a method suitable for direct detection of four esters, phenylpropionate among them, in dried blood spots after Sustanon 250 injections.9
Storage and handling
Sources in this part
What is not known
None of the summaries of the PubMed records and the one ClinicalTrials.gov entry returned by the searches described above describes testosterone phenylpropionate given alone to people, so its own time course, duration of action, bioavailability and safety are not described in the sources cited here.1
The half-life is stated in two ways: 36 hours in the app and 2.5 days in the introduction of a 2022 chemistry paper that attributes the figure to a 2015 detection study whose PubMed summary gives none.2,5 The label figures for peak time (approximately 24-48 h) and return to the normal range (approximately 21 days) describe total testosterone after the blend, and the one pharmacokinetic study of a blend cited here reports a peak seven days after injection in patients with beta thalassaemia major.1,10
Frequently asked questions
What is the half-life of testosterone phenylpropionate?
The app lists a half-life of 36 hours (about 1.5 days) for testosterone phenylpropionate. A 2022 chemistry paper states 2.5 days in its introduction, citing a 2015 detection study.2 The labels, papers and study summaries cited here report no half-life measured for the ester alone.
What is testosterone phenylpropionate?
How much testosterone phenylpropionate is in Sustanon 250?
Each 1 ml ampoule of Sustanon 250 holds 60 mg of testosterone phenylpropionate on the UK label, with 30 mg testosterone propionate, 60 mg testosterone isocaproate and 100 mg testosterone decanoate.1
Is testosterone phenylpropionate banned by WADA?
Testosterone is named in section S1.1 of the WADA 2026 Prohibited List, which is prohibited at all times, in and out of competition, when administered exogenously.12 The text of S1.1 also covers "other substances with a similar chemical structure or similar biological effect(s) including their esters".12 The text of the list does not print the word phenylpropionate, so the closest wording is "including their esters".12
How long does testosterone phenylpropionate take to peak?
The app lists a time to peak of 36 hours for testosterone phenylpropionate. For total testosterone after the four-ester Sustanon 250, the UK label gives a tmax of approximately 24-48 h, and a 1993 study of a four-ester mix in patients with beta thalassaemia major reported peak values seven days after injection.1,10
Has testosterone phenylpropionate been studied on its own in people?
None of the summaries of the records returned by a search of PubMed on 16 November 2026 or by a search of ClinicalTrials.gov describes people receiving testosterone phenylpropionate as the only ester. The human studies identified gave it within a mixture, such as Sustanon 250 in a 2019 trial of 18 older men.11
What are the side effects of testosterone phenylpropionate?
No study summary or paper cited here reports side effects of testosterone phenylpropionate given alone. The UK label for the four-ester Sustanon 250 lists adverse reactions associated with androgen therapy in general, among them polycythaemia, fluid retention, hypertension, acne and gynaecomastia, and states that injectables in general may cause a local reaction at the injection site.1 The label's table lists more, among them progression of a sub-clinical prostatic cancer, depression, hepatic function abnormal, and increased PSA and haematocrit.1
Can testosterone phenylpropionate be detected in a drug test?
In published research studies, methods have detected the intact ester. Solheim and colleagues (2022) describe a dried blood spot method suitable for direct detection of four testosterone esters, phenylpropionate among them, after Sustanon 250 injections in 9 men; Sustanon was detected in all subjects for at least 5 days, with a detection window up to 14 days for three of the esters that the summary does not name.9
Guides, tools and comparisons
References
- Aspen Pharma Trading Limited. Sustanon 250, 250mg/ml solution for injection: Summary of Product Characteristics (electronic medicines compendium, UK). Updated 16 February 2026. emc SmPC
- Turza A, Popescu V, Mare L, Borodi G. Structural Aspects and Intermolecular Energy for Some Short Testosterone Esters. Materials (Basel) 2022. PMC9611952
- National Center for Biotechnology Information. PubChem Compound Summary for CID 14743, Testosterone phenylpropionate. Accessed 16 November 2026. PubChem CID 14743
- Sustanon 250 (250 mg testosterone esters solution for injection): New Zealand data sheet. Medsafe, revision of 14 January 2026. Medsafe data sheet
- Forsdahl G, et al. Detection of testosterone esters in blood. Drug Test Anal 2015. PMID 26695486
- Forsdahl G, et al. Quantification of endogenous steroid sulfates and glucuronides in human urine after intramuscular administration of testosterone esters. Steroids 2020. PMID 32097612
- Büyükgebiz A. Treatment of constitutional delayed puberty with a combination of testosterone esters. Horm Res 1995. PMID 8719438
- ClinicalTrials.gov. NCT01454011: The Effect of Testosterone Replacement on the High Density Lipoprotein Cholesterol Subgroups. Gulhane School of Medicine; record updated 2011. NCT01454011
- Solheim SA, et al. Stability and detectability of testosterone esters in dried blood spots after intramuscular injections. Drug Test Anal 2022. PMID 33733610
- Katz M, et al. Pharmacokinetics of sex steroids in patients with beta thalassaemia major. J Clin Pathol 1993. PMID 8157756
- Gharahdaghi N, et al. Testosterone therapy induces molecular programming augmenting physiological adaptations to resistance exercise in older men. J Cachexia Sarcopenia Muscle 2019. PMC6903447
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. In force 1 January 2026. WADA 2026 list
- Tretzel L, et al. Use of dried blood spots in doping control analysis of anabolic steroid esters. J Pharm Biomed Anal 2014. PMID 24713476
- Büyükgebiz A. Treatment of constitutional delayed puberty with a combination of testosterone esters. Turk J Pediatr 1993. PMID 8160278